James Pink Medical Device Risk Management. Requirements The medical device industry is highly regulated and based upon a device specific risk rating for.
Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA.
Effectiveness of Simulation in Healthcare Joseph Barton, MD, MHMS September 18, 2014.
“Progenitor Cell Therapy in AMI After Meta-Analyses Results ? Pro“ “Progenitor Cell Therapy in AMI After Meta-Analyses Results ? Pro“ Andreas M. Zeiher,
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
PHYSIOLOGICAL AND LABORATORY MARKERS OF DRUG EFFECT Arthur J. Atkinson, Jr., M.D. Senior Advisor in Clinical Pharmacology Clinical Center, NIH.
1 November 2005 ODAC: DOXIL ®, AIDS-related KS ODAC Discussion on Accelerated Approval 8 November 2005 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
Regional Anaesthesia and Thromboprophylaxis Dr Kate Fogg Royal Brompton Hospital.
Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.
